NCT07164976View on ClinicalTrials.gov

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

September 1, 2029

Study Completion Date

April 1, 2030

Conditions
Breast Cancer
Interventions
DRUG

Ribociclib 400mg

phase 1b cohort 1

DRUG

Ribociclib 600mg

Phase 1b cohort 2

DRUG

Ribociclib 600mg

phase 2

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Nagoya City University

OTHER

NCT07164976 - Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter